Matthew Feinsod
CIK: 0001716950
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Kalaris Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Mar 19, 2026KLRS
Kalaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
135K shares- - Apr 10, 2025KLRS
Kalaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
70.6K shares- - Apr 10, 2025KLRS
Kalaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
101K shares- - Mar 18, 2025KLRS
Kalaris Therapeutics, Inc.
Award(A)Direct4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 19, 2026 | KLRS Kalaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 135,000 | - | - | Direct |
| Apr 10, 2025 | KLRS Kalaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 70,551 | - | - | Direct |
| Apr 10, 2025 | KLRS Kalaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 101,000 | - | - | Direct |
| Mar 18, 2025 | KLRS Kalaris Therapeutics, Inc. | Award(A) | 4,030 | - | - | Direct |
1-4 of 4 transactions
About Feinsod Matthew
Feinsod Matthew (SEC CIK 0001716950) files insider reports with the SEC as Chief Medical Officer of Kalaris Therapeutics, Inc. (KLRS).
Signal8 holds 4 ownership filings by Feinsod Matthew (1 Form 3, 3 Form 4), filed between Mar 18, 2025 and Mar 20, 2026. Those filings report 4 transactions, from Mar 18, 2025 to Mar 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Feinsod Matthew's filings is in BERKELEY HEIGHTS, NJ.
Recent filings by Feinsod Matthew
Other insiders filing for Kalaris Therapeutics, Inc. (KLRS)
- Vandekop Amy O'Leary, VP, Corporate Controller
- KEATING LAURIE, Director
- Bayko Liisa Ann, Chief Financial Officer
- Jovan-Embiricos Morana, Director
- Ferrara Napoleone, Director
- Hallal David, Director